John B. Haanen on Muck Rack

John B. Haanen

Amsterdam
As seen in: ESMO, Immuno-Oncology Technology, Nature, Wiley Online Library, MDPI, JAMA (The Journal of the American Medical Association), Medscape, Science Magazine, Cell Press, EClinicalMedicine, The Lancet, Healio and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with John B.

Contact John B., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Publisher Correction: Clinical development of cancer vaccines

|
By John B. Haanen, Ton N. M. Schumacher, Jonathan Kagan, Edward F. Fritsch, Catherine J. Wu
| Nature Verified
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04241-9, published online 11 March 2026. In the version of the article initially published, in Fig. 4, the checkmarks in the top two rows in the “Good DC quality?” column should have been X’s. This has now been corrected in the HTML and PDF versions of the article. About this article Haanen, J.B., Schumacher, T.N.M., Kagan, J.C. et al. Publisher Correction: Clinical development of cancer vaccines. Nat Med (2026).
Open in Who Shared Issue with article?

Clinical development of cancer vaccines

|
By John B. Haanen, Jonathan Kagan, Edward F. Fritsch, Catherine J. Wu, Ton N. M. Schumacher
| Nature Verified
Abstract The limitations of current immune checkpoint inhibitor therapies highlight a need for improved strategies to expand tumor-reactive T cell repertoires in a way that is safe, selective and efficient. Cancer vaccines hold potential to achieve this goal, but the profound success of vaccines for infectious diseases has not yet translated to the cancer setting.
Open in Who Shared Issue with article?

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy - Nature Communications

|
By Emily Jackson, Claudia Gottstein, Sebastian Hymson, Brenda Raud, Asaf Poran, John B. Haanen
| Nature Verified
Abstract Neoantigen-based adoptive T cell therapies (ACTs) represent a promising avenue in cancer immunotherapy due to their exquisite tumor specificity. The first cell-based immunotherapy for a solid tumor, comprising tumor-infiltrating lymphocytes, recently received FDA approval. Building on this, we designed a distinct ACT approach, where T cell responses against personalized neoantigens are systematically generated from autologous peripheral blood.
Open in Who Shared Issue with article?
See all 30 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified